Why did the FDA refuse Moderna’s flu shot?

Regulators said the application couldn’t be accepted

U.S. health officials declined to accept an application from Moderna seeking approval for an mRNA-based influenza vaccine, saying the company’s clinical data did not meet the agency’s standards for an ‘‘adequate and well‑controlled’’ trial. The agency flagged in particular that the shot was compared in its study against a vaccine the FDA considered not the best available standard of care, which left reviewers unconvinced the trial demonstrated superiority or non‑inferiority in a way that supports licensure.

The refusal reflected a rare break between agency reviewers and top leadership. Senior internal reviewers recommended that the application be reviewed; a senior FDA official ultimately overruled those reviewers and refused the application. The agency has defended that decision publicly as based on scientific and trial‑design concerns. Moderna says it has requested a meeting to discuss the refusal and is seeking to resolve the issues.

Why it matters

• The decision could slow the introduction of a new platform for seasonal influenza vaccines in the U.S., at a time when mRNA technology is being used for other infectious disease vaccines.
• Industry and some public‑health experts say the move may chill investment and development plans for updated or novel flu shots, especially if regulators and manufacturers disagree about trial comparators and endpoints.
• The dispute has become politicized because it comes amid broader debates about vaccine policy and leadership at federal health agencies.

What comes next

Moderna has asked for a meeting with the FDA to clarify the agency’s concerns and explore next steps. The company and the regulator will need to agree on a redesigned trial or additional data that directly address the comparator and study‑design issues before the application can be accepted for review.